Literature DB >> 20587520

HuR regulates beta-tubulin isotype expression in ovarian cancer.

Giuseppina Raspaglio1, Ilaria De Maria, Flavia Filippetti, Enrica Martinelli, Gian Franco Zannoni, Silvia Prislei, Gabriella Ferrandina, Shohreh Shahabi, Giovanni Scambia, Cristiano Ferlini.   

Abstract

The supply of oxygen and nutrients to solid tumors is inefficient because cancer tissues have an inadequate number of microvessels, thus inducing the selective growth of the most aggressive cancer cells. This explains why many of the factors underlying a poor prognosis are induced in hypoxic/hypoglycemic conditions. Among these factors, a prominent role in several solid tumors is played by the class III beta-tubulin gene (TUBB3). The study described here reveals that glucose deprivation enhances TUBB3 expression at both the gene and protein levels in A2780 ovarian cancer cells. In silico analysis of TUBB3 mRNA sequence predicted a putative binding site for the RNA-binding protein Hu antigen (HuR) in the 3' flanking untranslated region. A hypoglycemic-dependent engagement of this site was shown using RNA pull-down and ribonucleoimmunoprecipitation techniques. Thereafter, HuR gene silencing revealed that TUBB3 translation is HuR dependent in hypoglycemia because HuR silencing inhibited the entry of TUBB3 mRNA into cytoskeletal and free polysomes. Finally, the clinical value of this finding was assessed in a clinical cohort of 46 ovarian cancer patients in whom it was found that HuR cytoplasmic staining was associated with high levels of TUBB3 and poor survival. (c)2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20587520     DOI: 10.1158/0008-5472.CAN-09-4656

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  32 in total

1.  Insights from the HuR-interacting transcriptome: ncRNAs, ubiquitin pathways, and patterns of secondary structure dependent RNA interactions.

Authors:  Georges St Laurent; Dmitry Shtokalo; Mohammad Heydarian; Andrey Palyanov; Dmitry Babiy; Jianhua Zhou; Ajit Kumar; Silvio Urcuqui-Inchima
Journal:  Mol Genet Genomics       Date:  2012-10-04       Impact factor: 3.291

2.  HuR is a post-transcriptional regulator of core metabolic enzymes in pancreatic cancer.

Authors:  Richard A Burkhart; Danielle M Pineda; Saswati N Chand; Carmella Romeo; Eric R Londin; Edward D Karoly; Joseph A Cozzitorto; Isidore Rigoutsos; Charles J Yeo; Jonathan R Brody; Jordan M Winter
Journal:  RNA Biol       Date:  2013-06-13       Impact factor: 4.652

Review 3.  Clinical significance of HuR expression in human malignancy.

Authors:  Ioly Kotta-Loizou; Constantinos Giaginis; Stamatios Theocharis
Journal:  Med Oncol       Date:  2014-08-13       Impact factor: 3.064

4.  Human antigen R as a predictive marker for response to gemcitabine-based chemotherapy in advanced cisplatin-resistant urothelial cancer.

Authors:  Yasuyoshi Miyata; Kensuke Mitsunari; Asai Akihiro; Shin-Ichi Watanabe; Tomohiro Matsuo; Kojiro Ohba; Hideki Sakai
Journal:  Oncol Lett       Date:  2016-12-12       Impact factor: 2.967

Review 5.  Susceptibility of cytoskeletal-associated proteins for tumor progression.

Authors:  Abiola Abdulrahman Ayanlaja; Xiaoliang Hong; Bo Cheng; Han Zhou; Kouminin Kanwore; Piniel Alphayo-Kambey; Lin Zhang; Chuanxi Tang; Muinat Moronke Adeyanju; Dianshuai Gao
Journal:  Cell Mol Life Sci       Date:  2021-12-29       Impact factor: 9.261

6.  The ADNP derived peptide, NAP modulates the tubulin pool: implication for neurotrophic and neuroprotective activities.

Authors:  Saar Oz; Yanina Ivashko-Pachima; Illana Gozes
Journal:  PLoS One       Date:  2012-12-14       Impact factor: 3.240

7.  Class III β-tubulin counteracts the ability of paclitaxel to inhibit cell migration.

Authors:  Anutosh Ganguly; Hailing Yang; Fernando Cabral
Journal:  Oncotarget       Date:  2011-05

Review 8.  Multiple functions of the RNA-binding protein HuR in cancer progression, treatment responses and prognosis.

Authors:  Jun Wang; Yan Guo; Huili Chu; Yaping Guan; Jingwang Bi; Baocheng Wang
Journal:  Int J Mol Sci       Date:  2013-05-10       Impact factor: 5.923

9.  MiR-200c and HuR in ovarian cancer.

Authors:  Silvia Prislei; Enrica Martinelli; Marisa Mariani; Giuseppina Raspaglio; Steven Sieber; Gabriella Ferrandina; Shohreh Shahabi; Giovanni Scambia; Cristiano Ferlini
Journal:  BMC Cancer       Date:  2013-02-08       Impact factor: 4.430

10.  Free testosterone drives cancer aggressiveness: evidence from US population studies.

Authors:  Shohreh Shahabi; Shiquan He; Michael Kopf; Marisa Mariani; Joann Petrini; Giovanni Scambia; Cristiano Ferlini
Journal:  PLoS One       Date:  2013-04-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.